This study is testing a new treatment called Ixo-vec for a condition called neovascular age-related macular degeneration (nAMD), which affects the eyes and can lead to vision loss. *Neovascular* means new blood vessels are growing where they shouldn't, in this case, in the retina, a part of the eye. Participants will be given an injection directly into the eye (intravitreal injection) and will be compared to another standard treatment. The study will last about 56 weeks, and will measure changes in vision clarity, called best corrected visual acuity (BCVA). **Key Points:** - The study involves a single eye injection and requires several visits over a year. - Participants must be 50 or older and willing to follow study rules. - Prior gene therapy or certain eye surgeries exclude participation. The study will also check if the treatment is safe and works well. If you have uncontrolled high blood pressure, certain heart problems, or eye infections, you might not be able to join. Safety will be closely monitored, and the study is looking for people who have had some response to current eye treatments.